BRENTFORD, ENGLAND, UNITED KINGDOM, October 14, 2025 / EINPresswire.com / -- The global CRISPR gene-editing market is expected to witness significant growth, projected to rise from a valuation of US$ ...
CRISPR-Cas9 gene editing holds immense potential in the field of precision medicine for liver diseases. This innovative technology permits researchers to precisely modify genes linked to liver ...
Zacks Investment Research on MSN
Can NTLA's In Vivo Pipeline Aid Long-Term Growth Amid Competition?
Intellia Therapeutics NTLA has made meaningful progress with the development of its in vivo programs. The company is currently advancing two late-stage in vivo candidates — lonvo-z (or, NTLA-2002) for ...
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the acceptance of an abstract for oral ...
Grapevine (Vitis vinifera L.) holds significant economic and cultural value, driving the need for rapid genetic improvement to meet climatic and market demands. While traditional breeding is slow and ...
DUBLIN and SAN DIEGO, March 27, 2025 /PRNewswire/ -- ERS Genomics Limited ('ERS'), the CRISPR licensing company, and Jumpcode Genomics ('Jumpcode'), a life science tools company improving and reducing ...
Last week, the University of California filed an opening brief to appeal a decision by the U.S. Patent Trial and Appeal Board, or PTAB, which denied UC patent claims for CRISPR-Cas9 technology in ...
Importantly, the researchers at Boston Children's Hospital utilized the Nabsys OhmX Platform to identify a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback